The global imperative for early and accurate cancer diagnosis — with cancer incidence projected to reach 28.4 million cases annually by 2040 — combined with the shift toward minimally invasive diagnostic protocols and the expanding application of molecular profiling requiring high-quality tissue specimens, is driving sophisticated biopsy device innovation, with the Needle Based...